Haematologica Reports 2005; 1(issue 2): 30-32
[prev][index]
?The role of minimal residual disease elimination in the
outcome of chronic lymphocytic leukemia
?M.
Hallek
?Universität zu Köln, Klinik I für Innere Medizin,
Köln, Germany
?There have been significant changes during the past few decades
in the management of chronic lymphocytic leukemia (CLL), a disease
with a very heterogeneous outcome ranging from survival for
decades, without evidence of progression, to rapid transformation
into more aggressive disease and early death.1
An increasing awareness of the prognostic factors and molecular
heterogeneity of CLL has helped to identify distinct risk
categories, enabling early identification of patients likely to
develop more aggressive disease. In addition, newer treatment
agents and strategies, including monoclonal antibodies and
hematopoietic stem cell transplantation (SCT), have resulted in
much higher complete response (CR) rates than seen previously with
conventional therapy. [>Read full article in
PDF]
